Reinovax Biologics

Founded in 2017 and based in Shanghai, China, Shanghai Reinovax Biologics Co. , Ltd. , trading as Reinovax Biologics, is a biotechnology company focused on the research, development, and industrialization of novel vaccines and recombinant protein-based biopharmaceuticals. In 2019, Shanghai Reinovax Biologics Co.

, Ltd. initiated pilot-scale development for its proprietary 24-valent pneumococcal conjugate vaccine (PCV24). To support scaling, it established two wholly owned subsidiaries: Shanghai Weizhou Biotech Co. , Ltd.

in March 2021, which operates a GMP-compliant pilot production facility, and Changchun Reinovax Biopharmaceutical Co. , Ltd. in May 2020, which oversees large-scale GMP vaccine manufacturing. By 2024, the company completed construction of its Changchun manufacturing site and entered Phase II clinical trials for PCV24 targeting adults and Phase I trials for pediatric populations.

In January 2026, it raised CNY 200 million in series B funding. The company works with medical researchers and biopharmaceutical firms to provide innovative vaccine solutions. Core products include PCV24, a 24 valent pneumococcal conjugate vaccine designed to cover over 90 percent of pathogenic serotypes in China. The company is also developing a novel meningococcal vaccine and offers contract development and manufacturing services.

The company generates revenue through R&D partnerships, contract biomanufacturing services, and anticipated future sales of proprietary vaccine products pending regulatory approval. Reinovax Biologics plans to initiate clinical trials for the adult indication of its PCV24 vaccine and advance trials for the infant indication.